{
    "xml": "<topic id=\"PHP3223\" outputclass=\"drug\" rev=\"1.16\" type=\"drug\" namespace=\"/drugs/buprenorphine-with-naloxone\" basename=\"buprenorphine-with-naloxone\" title=\"BUPRENORPHINE WITH NALOXONE\">\n<title>BUPRENORPHINE WITH NALOXONE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_87\" namespace=\"/interactions/list-of-drug-interactions/analgesics/opioid-analgesics/buprenorphine\">Buprenorphine</xref>\n</p>\r\n<p outputclass=\"constituentDrugs\">The properties listed below are those particular to the combination only. For the properties of the components please consider, <xref format=\"dita\" href=\"#PHP2680\" namespace=\"/drugs/buprenorphine\">buprenorphine</xref>, <xref format=\"dita\" href=\"#PHP202\" namespace=\"/drugs/naloxone-hydrochloride\">naloxone hydrochloride</xref>.</p>\n<data name=\"vtmid\">425741009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_110392128\" title=\"Opioids\">Opioids</xref>\n</data>\n</data>\r\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_441568498\" title=\"Opioid receptor antagonists\">Opioid receptor antagonists</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP49924\" outputclass=\"indicationsAndDose\" rev=\"1.22\" parent=\"/drugs/buprenorphine-with-naloxone\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Adjunct in the treatment of opioid dependence (dose expressed as buprenorphine)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By sublingual administration</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 2&#8211;4&#8239;mg once daily, an additional dose of 2&#8211;4&#8239;mg may be administered on day 1 depending on the individual patient&#8217;s requirement, increased in steps of 2&#8211;8&#8239;mg, adjusted according to response, total weekly dose may be divided and given on alternate days or 3 times weekly; maximum 24&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49651\" outputclass=\"nationalFunding\" rev=\"1.8\" parent=\"/drugs/buprenorphine-with-naloxone\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> has advised (February 2007) that Suboxone<tm tmtype=\"reg\"/> should be restricted for use in patients in whom methadone is not suitable.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP3223-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/buprenorphine-with-naloxone\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76656\" title=\"Sublingual tablet\" namespace=\"/drugs/buprenorphine-with-naloxone/sublingual-tablet\">Sublingual tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"2\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78560\" namespace=\"/treatment-summaries/substance-dependence\" title=\"Substance dependence\" count=\"1\" rel=\"backlink\">Substance dependence</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_87\" namespace=\"/interactions/list-of-drug-interactions/analgesics/opioid-analgesics/buprenorphine\" title=\"Buprenorphine\" count=\"1\" rel=\"link\">Buprenorphine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP2680\" namespace=\"/drugs/buprenorphine\" title=\"BUPRENORPHINE\" count=\"1\" rel=\"link\">BUPRENORPHINE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP202\" namespace=\"/drugs/naloxone-hydrochloride\" title=\"NALOXONE HYDROCHLORIDE\" count=\"1\" rel=\"link\">NALOXONE HYDROCHLORIDE</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76656\" namespace=\"/drugs/buprenorphine-with-naloxone/sublingual-tablet\" title=\"Sublingual tablet\" count=\"1\" rel=\"link\">Sublingual tablet</xref>\n</links>\n</topic>",
    "id": "PHP3223",
    "outputclass": "drug",
    "rev": "1.16",
    "type": "drug",
    "namespace": "/drugs/buprenorphine-with-naloxone",
    "basename": "buprenorphine-with-naloxone",
    "title": "BUPRENORPHINE WITH NALOXONE",
    "interactants": [
        {
            "id": "bnf_int_87",
            "label": "Buprenorphine"
        }
    ],
    "constituents": [
        {
            "id": "PHP2680",
            "label": "buprenorphine"
        },
        {
            "id": "PHP202",
            "label": "naloxone hydrochloride"
        }
    ],
    "vtmid": "425741009",
    "drugClassification": [
        "Opioids",
        "Opioid receptor antagonists"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Adjunct in the treatment of opioid dependence (dose expressed as buprenorphine)",
                        "html": "Adjunct in the treatment of opioid dependence (dose expressed as buprenorphine)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "sublingual administration"
                    ],
                    "textContent": "By sublingual administration",
                    "html": "By sublingual administration"
                },
                "adult": [
                    {
                        "textContent": "Initially 2&#8211;4 mg once daily, an additional dose of 2&#8211;4 mg may be administered on day 1 depending on the individual patient&#8217;s requirement, increased in steps of 2&#8211;8 mg, adjusted according to response, total weekly dose may be divided and given on alternate days or 3 times weekly; maximum 24 mg per day.",
                        "html": "<p>Initially 2&#8211;4&#8239;mg once daily, an additional dose of 2&#8211;4&#8239;mg may be administered on day 1 depending on the individual patient&#8217;s requirement, increased in steps of 2&#8211;8&#8239;mg, adjusted according to response, total weekly dose may be divided and given on alternate days or 3 times weekly; maximum 24&#8239;mg per day.</p>"
                    }
                ]
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised (February 2007) that Suboxone should be restricted for use in patients in whom methadone is not suitable.",
                "html": "<p>The <i>Scottish Medicines Consortium</i> has advised (February 2007) that Suboxone<tm tmtype=\"reg\"/> should be restricted for use in patients in whom methadone is not suitable.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76656",
                "label": "Sublingual tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78560",
                "label": "Substance dependence",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_87",
                "label": "Buprenorphine",
                "type": "interaction"
            }
        ],
        "drug": [
            {
                "id": "PHP2680",
                "label": "BUPRENORPHINE",
                "type": "drug"
            },
            {
                "id": "PHP202",
                "label": "NALOXONE HYDROCHLORIDE",
                "type": "drug"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76656",
                "label": "Sublingual tablet",
                "type": "medicinalForm"
            }
        ]
    }
}